Compare Lithium Americas Corp (LAC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Merck & Co., Inc. — how do they compare? Lithium Americas Corp trades at $2.36 (market cap $850.38M), while Merck & Co., Inc. trades at $145.68 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 413.1× Lithium Americas Corp's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and Merck & Co., Inc. for 98 Days on average.
| LAC | MRK | |
|---|---|---|
Market Cap | $850.38M | $351.28B |
Volume | 8,804,637 | 7,969,665 |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $156.43 |
52-Week Low | $2.36 | $82.49 |
Typical Hold Time | 27 Days | 98 Days |
Enterprise Value | $1.19B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.36, down 2.28% with bearish technical signals but positive analyst sentiment. The company shows negative profitability metrics with ROE at -9.56% and net income of -$122.09M for 2025, though it has beaten EPS estimates in recent quarters. Strong financing activity ($1.14B in 2025) supports Thacker Pass development, a key growth catalyst.
Investment outlook balances development potential against current losses. The consensus price target of $4.00 suggests 70% upside, but execution risks and lithium price volatility remain concerns. Construction progress at Thacker Pass could drive rerating, though the stock faces near-term pressure from negative cash flow and market skepticism.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
